Share This Page
Drugs in ATC Class D07A
✉ Email this page to a colleague
Subclasses in ATC: D07A - CORTICOSTEROIDS, PLAIN
Market Dynamics and Patent Landscape for ATC Class D07A - Corticosteroids, Plain
What are the current market trends for corticosteroids, plain?
The global corticosteroids market, specifically the D07A class, has been expanding driven by increased demand in dermatology, rheumatology, and respiratory conditions. Factors influencing growth include rising prevalence of autoimmune diseases, psoriasis, and asthma, alongside advancements in topical formulations.
Projection: The market size for topical corticosteroids classified under D07A was valued at approximately $4 billion in 2022, expanding at a compound annual growth rate (CAGR) of 3.5% through 2027[1].
Key drivers:
- Increasing chronic skin conditions: Psoriasis, eczema, and dermatitis.
- Growing aging population: Elevated incidence of skin disorders.
- Enhanced formulations: Development of low-potency corticosteroids reduces side effects.
How is the patent landscape structured for corticosteroids, plain?
Patent filing and expiration trends
Major corticosteroid formulations under D07A have seen extensive patenting from global pharmaceutical companies, with peak filings during 2000-2010. Patents typically have 20-year lifespans from filing dates, with many expiring between 2020-2030, opening the market for generics.
Key patent types
- Composition patents: Cover specific chemical formulations and their combinations.
- Use patents: Cover new therapeutic indications or delivery methods.
- Formulation patents: Cover specific topical delivery systems, including gels, creams, and ointments.
Notable patent families
- Clobetasol Propionate: Critical patents for high-potency use expired or are close to expiration in various jurisdictions, enabling generics.
- Hydrocortisone: Multiple active patents expired in the past decade, leading to a generic proliferation.
- Betamethasone Dipropionate: Several patents still active, mainly in formulation and novel delivery system spheres, with expiration dates extending into 2025-2030.
Patent challenges and litigation
Patent challenges frequently emerge post-expiration periods, especially where patent expiry opens markets for generics. In some instances, secondary patents attempt to extend exclusivity, focusing on formulations or combinations.
What are the predominant players and their strategies?
Leading companies include Novartis, Teva, Mylan, and Sandoz. Strategies encompass:
- Developing new formulations with reduced side effects.
- Securing patent rights over novel delivery mechanisms.
- Entering licensing agreements for established corticosteroid molecules.
How do regulatory policies affect the market?
Regulatory environments, such as the FDA in the U.S. and EMA in Europe, impose strict guidelines on topical corticosteroid safety and efficacy. Patent term extensions are permitted in some jurisdictions, contingent on regulatory delays. The approval pathway for generic products hinges on demonstrating bioequivalence, especially post-patent expiry.
What challenges face market players?
- Patent cliffs, especially around high-potential molecules like clobetasol.
- Differentiating in a saturated market.
- Navigating regulatory hurdles efficiently.
- Addressing safety concerns related to potency and long-term use.
What future opportunities are visible?
- Development of lower-potency or combination formulations.
- Innovations in delivery systems targeting better skin absorption.
- Repurposing existing corticosteroids for new therapeutic indications.
- Strategic patent filing in emerging markets with rising demand.
Key Dates and Patent Expirations (selected)
| Compound | Original Filing Year | Expiry Year | Notes |
|---|---|---|---|
| Clobetasol Propionate | 1974 | 2025 | Patent rights in EU and US approaching expiry |
| Hydrocortisone | 1947 | 2022-2024 | Patent expiration has enabled generics |
| Betamethasone Dipropionate | 1963 | 2025-2030 | Several formulation patents active |
Conclusion
The corticosteroids, plain (ATC D07A) market faces a phase of increased generic penetration as many primary patents expire. Innovation focuses on formulation and delivery improvements to extend product lifecycle. Companies that adapt to regulatory changes, invest in formulation R&D, and leverage patent strategies will position themselves favorably.
Key Takeaways
- The dominant patents for corticosteroids under D07A have predominantly expired or are nearing expiration, creating opportunities for generics.
- Market growth is driven by rising dermatological and autoimmune conditions, especially in aging populations.
- Patent strategies are shifting toward formulation innovations and delivery mechanisms.
- Regulatory pathways favor biosimilar or generic entrants post-patent expiry, facilitating market entry.
- Emerging markets present significant growth potential due to increasing healthcare expenditure and disease prevalence.
Frequently Asked Questions
-
What factors influence the expiration of corticosteroid patents?
Patent expiration depends on filing dates, patent term adjustments, and whether any extensions or supplementary protection certificates are granted. -
How do formulation patents differ from composition patents?
Composition patents protect the active molecule, while formulation patents claim specific delivery systems, excipients, or formulations designed to optimize drug delivery or reduce side effects. -
What regulatory challenges exist for corticosteroids?
Ensuring bioequivalence for generics, safety profile assessment, and meeting guidelines for potency and side effects are primary regulatory hurdles. -
Are there specific markets with delayed patent expiration?
Yes, jurisdictions like Japan and certain emerging markets may grant longer exclusivity or supplementary patents, delaying generic entry. -
What is the main growth driver for the corticosteroid plain market?
The increase in chronic dermatological and autoimmune diseases, coupled with aging populations, sustains demand.
References
[1] Market Research Future. (2022). Topical Corticosteroids Market Analysis. Retrieved from https://www.marketresearchfuture.com
More… ↓
